Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00181155 · ClinicalTrials.gov registry record · Phase 2
Intravenous Allopurinol in Heart Failure
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00181155: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT00181155 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00181155, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study tests the hypothesis that allopurinol, a xanthine oxidase inhibitor, improves heart metabolism in patients with heart failure.
Interventions
- DRUG Placebo
- DRUG Allopurinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2004-11 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00181155
The ClinicalTrials.gov registry entry for NCT00181155 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00181155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00181155 about?
NCT00181155 is a clinical study titled "Intravenous Allopurinol in Heart Failure". This study tests the hypothesis that allopurinol, a xanthine oxidase inhibitor, improves heart metabolism in patients with heart failure.
What is the current status of trial NCT00181155?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2004-11. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00181155?
The interventions under investigation include: Placebo (DRUG), Allopurinol (DRUG).
Who is sponsoring clinical trial NCT00181155?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.